1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity
作者:Karen Miller-Moslin、Stefan Peukert、Rishi K. Jain、Michael A. McEwan、Rajesh Karki、Luis Llamas、Naeem Yusuff、Feng He、Yanhong Li、Yingchuan Sun、Miao Dai、Lawrence Perez、Walter Michael、Tao Sheng、Huangshu Lei、Rui Zhang、Juliet Williams、Aaron Bourret、Arun Ramamurthy、Jing Yuan、Ribo Guo、Melissa Matsumoto、Anthony Vattay、Wieslawa Maniara、Adam Amaral、Marion Dorsch、Joseph F. Kelleher
DOI:10.1021/jm900309j
日期:2009.7.9
Abnormal activation of the Hedgehog (Hh) signaling pathway has been linked to several types of human cancers, and the development of small-molecule inhibitors of this pathway represents a promising route toward novel anticancer therapeutics. A cell-based screen performed in our laboratories identified a new class of Hh pathway inhibitors, 1-amino-4-benzylphthalazines, that act via antagonism of the
Hedgehog(Hh)信号传导途径的异常激活与几种类型的人类癌症有关,并且该途径的小分子抑制剂的发展代表了一种通往新型抗癌疗法的有前途的途径。在我们实验室中进行的基于细胞的筛选确定了新型的Hh通路抑制剂1-氨基-4-苄基酞嗪,它们通过对平滑受体的拮抗作用发挥作用。合成了多种类似物,并确定了它们的构效关系。这种优化导致发现了高亲和力的平滑化拮抗剂,其中一种在体内得到了进一步的分析。该化合物在神经母细胞瘤的遗传小鼠模型中显示出良好的药代动力学特征,并且还可以使肿瘤消退。